transOMIC

Transomic Technologies, Inc. operated as a biotechnology firm focused on developing and commercializing research tools for the life sciences market before ceasing operations on January 1, 2024. The company was founded in 2012 by Blake Simmons (CEO), Gwen Fewell (Chief Commercial Officer), and Rusla Du Breuil (Chief Technology Officer). The leadership team had a shared history, having worked together at Open Biosystems and Research Genetics, bringing extensive experience in the biotechnology sector to their venture. Based at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, Transomic's business model revolved around collaborating with academic research labs to bring new technologies for gene manipulation to a global market.

The company provided a comprehensive portfolio of tools designed to accelerate research into the complexities of human disease, particularly in oncology, neuroscience, and metabolic disorders. Its product offerings centered on gene modulation, including RNA interference (RNAi) collections for gene knockdown, CRISPR reagents for genome editing, and extensive libraries of genes for overexpression studies. Transomic specialized in vector-based solutions and lentiviral technologies, offering one-stop workflow solutions for projects like cell screening and gene engineering. These tools were utilized by a client base that included life science researchers, academic institutions, and major pharmaceutical companies. The company generated revenue by selling these genomic tools and providing custom services, such as creating knockout cell lines and performing CRISPR screening assays.

Throughout its operation, Transomic achieved several key milestones. It partnered with Cold Spring Harbor Laboratory to commercialize next-generation RNAi tools and served as an archive site for high-quality gene collections for the National Institutes of Health (NIH). In November 2022, the company received a strategic investment of $375,000 from IMUNON, Inc. to support the development of IMUNON's DNA vaccine platform. A significant development occurred in August 2023 when Transomic entered into a non-exclusive licensing agreement with ERS Genomics, granting it access to the foundational CRISPR/Cas9 patent portfolio. Despite these advancements and partnerships, the company concluded its operations at the beginning of 2024. Keywords: Transomic Technologies, gene modulation, RNAi, CRISPR-Cas9, life sciences research tools, lentiviral vectors, gene expression, genome editing, HudsonAlpha, Blake Simmons, functional genomics, gene knockdown, molecular cloning, cell engineering, biotechnology reagents, custom vector construction, DNA vaccine collaboration, genomics laboratory, gene function analysis